News - Takeda Pharmaceuticals


Current filters:

Takeda Pharmaceuticals

Popular Filters

50 to 74 of 193 results

Three of Takeda's diabetes therapies get positive opinion from EMA unit


Japan's largest drugmaker Takeda (TSE: 4502) has received a positive opinion from the European Medicines…

DiabetesEuropeIncresyncPharmaceuticalRegulationTakeda PharmaceuticalsVipdometVipidia

Evolution of Japan's pharma wholesalers - by P Reed Maurer


Half of the definition for evolution (noun; a gradual process in which something changes especially into…

Asia-PacificFinancialMitsubishi TanabePharmaceuticalProductionSankyoShionogiTakeda Pharmaceuticals

$10 million milestone for Sucampo, as Takeda starts US selling of Amitiza for OIC


USA-based Sucampo Pharmaceuticals (Nasdaq: SCMP) says that it has received a $10 million milestone payment…

AmitizaFinancialGastro-intestinalsMarkets & MarketingNorth AmericaPharmaceuticalSucampoTakeda Pharmaceuticals

Takeda files BLA for vedolizumab for Crohn's and ulcerative colitis in USA


The US subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has submitted a Biologics…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says that its new diabetes products Nesina…

DiabetesKazanoMarkets & MarketingNesinaNorth AmericaOseniPharmaceuticalTakeda Pharmaceuticals

Regulatory briefs: Sanofi's Fluzone; Roche' RoActemra; Takeda's Rienso


French pharma major Sanofi (Euronext: SAN) today (June 10) announced that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalRegulationRocheSanofiTakeda PharmaceuticalsVaccines

Is the diabetes market facing a blockbuster-free future?


Japanese drug major Takeda's (TYO: 4502) recently announced positive late-stage results for new type…

DiabetesfasiglifamMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceuticals

Lundbeck and Takeda's Brintellix shows positive results in Ph III major depression study


Danish CNS specialist Lundbeck (LUND: DC) and partner Takeda Pharmaceutical (TYO: 4502), Japan's largest…

BrintellixLundbeckNeurologicalPharmaceuticalResearchTakeda Pharmaceuticalsvortioxetine

Top-line financial results from Japanese drug majors


Among a batch of Japanese drug majors presenting fiscal year 2013 (ended April 2013) financial results,…

Dainippon Sumitomo PharmaFinancialMitsubishi TanabePharmaceuticalShionogiTakeda Pharmaceuticals

Takeda to acquire Inviragen, gaining rights to promising vaccines


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into a definitive agreement to…

DENVaxInviragenMergers & AcquisitionsPharmaceuticalTakeda PharmaceuticalsVaccines

US Judge throws out verdict in Takeda Actos case


The US subsidiary of Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) USA announced that,…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Vedolizumab has potential to offer improvement over infliximab in UC


Surveyed US and EU5 gastroenterologists agree that new moderate to severe ulcerative colitis (UC) therapies…

EuropeGastro-intestinalsinfliximabJanssenMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares


The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

Takeda considering options over US Actos court ruling


The US subsidiary of Japan's largest drugmaker, Takeda Pharmaceuticals (TYO 4502), says that in the case…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world


The Japanese Ministry of Health, Labor and Welfare (MHLW) has said it supports the research and development…

Asia-PacificAstellas PharmaDaiichi SankyoEisaiFinancialHealthcarePharmaceuticalResearchShionogiTakeda PharmaceuticalsTropical diseases

Strong results from meta-analysis of Takeda's Velcade in multiple myeloma


Millennium, the USA-based oncology unit of Japan's largest drugmaker Takeda Pharmaceutical (TSE:4502),…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Takeda files for brentuximab vedotin approval in Japan; sanctioned by JPMA


Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) and its oncology subsidiary Millennium have…

AdcetrisAlinamin-F5Asia-PacificbrentuximabMillennium LaboratoriesOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Takeda expands Latin America footprint with new subsidiary in Ecuador


Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) says it is expanding its presence in Latin…

ManagementMarkets & MarketingPharmaceuticalSouth AmericaTakeda Pharmaceuticals

NPS Pharma regains rights to Revestive and Preotact from Takeda


USA-based NPS Pharmaceuticals (Nasdaq: NPSP) has re-gained the full worldwide rights from partner Takeda…

Anti-Arthritics/RheumaticsGastro-intestinalsGattexLicensingNatparaNPS PharmaceuticalsPharmaceuticalPreotactRevestiveTakeda Pharmaceuticals

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA


The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system…

EisaiEuropeFycompaGastro-intestinalsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

50 to 74 of 193 results

Back to top